Information intended for UK healthcare professionals only. The development of these Guidelines videos has been commissioned and funded by Intercept Pharma UK and Ireland Ltd. See bottom of the page for full disclaimer.

In these videos Dr Helen Jarvis (GP, West Road Medical Centre, Newcastle) and Dr Jeremy Cobbold (Consultant Hepatologist and Clinical Lead for Hepatology, Oxford University Hospitals NHS Foundation Trust) summarise the main messages covered in the live webinar ’Non-alcoholic steatohepatitis: identification, management, and referral pathways’, broadcast on 15 October 2020.

Identification and diagnosis of advanced fibrosis due to NASH

Referral and management of advance fibrosis due to NASH in secondary care

Primary and secondary care working together: a discussion on NASH

Identification, diagnosis, and treatment of early and advanced fibrosis dure to NASH: what do guidelines say?

Identification and diagnosis of advanced fibrosis due to NASH in primary care

References

  1. Tesfay M et al. Mo Med 2018; 115 (3): 225–229.
  2. McPherson S et al. Gut 2010; 59: 1265–1269.
  3. McPherson S et al. Am J Gastroenterol 2017; 112 (5): 740–751.
  4. Day J et al. J Appl Lab Med 2019; 3 (5): 815–826.
  5. Angulo P et al. Gastroenterology 2015; 149 (2): 389–397.e10.
  6. Dyson J et al. Front Gastroenterol 2014; 5: 277–286.
  7. NICE. Non-alcoholic fatty liver disease (NAFLD): assessment and management. NICE guideline 49. NICE, 2016. www.nice.org.uk/ng49
  8. Newsome P et al. Gut 2017; 0: 1–14.

Referral and management of advance fibrosis due to NASH in secondary care

References

  1. NICE. Non-alcoholic fatty liver disease (NAFLD): assessment and management. NICE guideline 49. NICE, 2016. www.nice.org.uk/ng49
  2. Armstrong M et al. J Hepatol 2012; 56: 234–240.
  3. Srivastava A et al. J Hepatol 2019; 71 (2): 371–378.
  4. Newsome P et al. Gut 2017; 0: 1–14.
  5. Tesfay M et al. Mo Med 2018; 115 (3): 225–229.
  6. Ekstedt M et al. Hepatology 2015; 61 (5): 1547–1554.
  7. Dyson J et al. Front Gastroenterol 2014; 5: 277–286.

Primary and secondary care working together: a discussion on NASH

References

  1. Tesfay M et al. Mo Med 2018; 115 (3): 225–229.
  2. McPherson S et al. J Hepatol 2015; 62 (5): 1148–1155.
  3. NHS. Non-alcoholic fatty liver disease. Available at: www.nhs.uk/conditions/non-alcoholic-fatty-liver-disease (accessed December 2020)
  4. Mansour D and McPherson S. Clin Med (Lond) 2018; 18 (Suppl 2): s60–s65.
  5. Dhamija E et al. Indian J Med Res 2019; 149 (1): 9–17
  6. European Association for the Study of the Liver (EASL). J Hepatol 2018; 69: 182–236.

Identification, diagnosis, and treatment of early and advanced fibrosis due to NASH: what do guidelines say?

References

  1. NICE. Non-alcoholic fatty liver disease (NAFLD): assessment and management. NICE guideline 49. NICE, 2016. www.nice.org.uk/ng49
  2. NICE. Obesity: identification, assessment and management. Clinical guideline 189. NICE, 2014. www.nice.org.uk/cg189
  3. Newsome P et al. Gut 2017; 0: 1–14.

These videos have been commissioned and funded by Intercept Pharma UK and Ireland Ltd and developed in partnership with Guidelines. Intercept Pharma UK and Ireland Ltd suggested the topic and presenters, and carried out full medical approval on all materials to ensure compliance with regulations. The presenters have been paid an honorarium. The views and opinions of the presenters are not necessarily those of Intercept Pharma UK and Ireland Ltd, or of Guidelines, its publisher, advisers, or advertisers. No part of this video may be reproduced in any form without the permission of the publisher.

UK-NAS-MED-00125

Date of preparation: December 2020